In a challenging market environment, Savara Inc. (NASDAQ:) stock has reached a 52-week low, dipping to $2.81. The pharmaceutical company, which specializes in rare respiratory diseases, has faced significant headwinds over the past year, reflected in a 1-year change showing a decline of 32.7%. Despite these challenges, InvestingPro data shows the company maintains strong liquidity with a current ratio of 17.7 and more cash than debt on its balance sheet. Investors have been cautious as the company navigates through a complex healthcare landscape, with the stock price struggling to regain momentum. This latest price level marks a concerning milestone for shareholders who are closely monitoring the company’s performance and potential recovery strategies. With analyst price targets ranging from $5 to $16, detailed analysis and additional insights are available through the comprehensive Pro Research Report, part of the extensive coverage of over 1,400 US stocks on InvestingPro.
In other recent news, Savara Inc. faced a price target cut from H.C. Wainwright, lowering it from $10 to $6, due to concerns over the company’s ability to meet patient identification goals for Molbreevi. However, the firm maintained a Buy rating on the stock. In contrast, Evercore ISI downgraded the stock from Outperform to In Line and reduced the price target to $5.00, citing manufacturing as the primary risk to approval. Piper Sandler maintained an Overweight rating on Savara with a $16.00 price target, emphasizing the potential of Savara’s MOLBREEVI as the first approved therapeutic for aPAP.
Savara reported earnings per share at ($0.12), slightly below the ($0.10) forecasted by Oppenheimer and consensus estimates. Additionally, the company announced a $100 million stock offering of 26,246,720 shares managed by firms such as Jefferies, Piper Sandler, and Guggenheim Securities.
In terms of company developments, Savara is on track for potential approval by the end of 2025 for MOLBREEVI in autoimmune pulmonary alveolar proteinosis (aPAP), assuming the treatment receives priority review. The company also launched an Expanded Access Program for molgramostim, a potential treatment for aPAP, and appointed Braden Parker as the new Chief Commercial Officer. These are among the recent developments at Savara.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
